We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.78B
AUM Growth
+$18.3M
Cap. Flow
+$443M
Cap. Flow %
15.93%
Top 10 Hldgs %
42.27%
Holding
179
New
61
Increased
32
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$37.6M
2
UNH icon
UnitedHealth
UNH
+$37.4M
3
UTHR icon
United Therapeutics
UTHR
+$29.3M
4
MRK icon
Merck
MRK
+$27.6M
5
A icon
Agilent Technologies
A
+$24.1M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$27.7M
2
CELG
Celgene Corp
CELG
+$26.8M
3
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$26.5M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$23.7M
5
ACOR
Acorda Therapeutics
ACOR
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 81.09%
2 Real Estate 3.47%
3 Financials 1.31%
4 Technology 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LRMR icon
151
Larimar Therapeutics
LRMR
$398M
$425K 0.02%
1,109
– –
KITE
152
DELISTED
Kite Pharma, Inc.
KITE
$351K 0.01%
6,300
– –
MGNX icon
153
MacroGenics
MGNX
$240M
$273K 0.01%
12,743
– –
XNCR icon
154
Xencor
XNCR
$1.59B
$245K 0.01%
20,000
– –
ACHV icon
155
Achieve Life Sciences
ACHV
$647M
– –
-51
Closed -$264K
AMGN icon
156
CALL
Amgen
AMGN
$209B
– –
-146,000
Closed -$22.4M
HCA icon
157
CALL
HCA Healthcare
HCA
$85.7B
– –
-66,300
Closed -$6.01M
IONS icon
158
CALL
Ionis Pharmaceuticals
IONS
$8.81B
– –
-98,200
Closed -$5.65M
IRWD icon
159
Ironwood Pharmaceuticals
IRWD
$614M
– –
-917,052
Closed -$9.26M
JAZZ icon
160
Jazz Pharmaceuticals
JAZZ
$16.2B
– –
-120,357
Closed -$21.2M
MYGN icon
161
Myriad Genetics
MYGN
$507M
– –
-74,800
Closed -$2.54M
SGMO
162
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-75,000
Closed -$832K
THC icon
163
CALL
Tenet Healthcare
THC
$21.8B
– –
-105,000
Closed -$6.08M
TXMD icon
164
TherapeuticsMD
TXMD
$23.5M
– –
-29,630
Closed -$11.6M
ACOR
165
DELISTED
Acorda Therapeutics
ACOR
– –
-5,674
Closed -$22.7M
ENDP
166
CALL
DELISTED
Endo International plc
ENDP
– –
-74,100
Closed -$5.9M
DERM
167
DELISTED
Dermira, Inc.
DERM
– –
-97,197
Closed -$1.71M
IPCI
168
DELISTED
Intellipharmaceuticals International Inc.
IPCI
– –
-35,405
Closed -$1.04M
KYTH
169
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
– –
-55,717
Closed -$4.2M
RCPT
170
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
– –
-124,800
Closed -$23.7M
CTRX
171
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
– –
-433,600
Closed -$26.5M
ZGNX
172
DELISTED
Zogenix, Inc.
ZGNX
– –
-475,101
Closed -$6.38M
MDVN
173
CALL
DELISTED
MEDIVATION, INC.
MDVN
– –
-107,400
Closed -$6.13M
3 4 5 6
7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Tekla Capital Management held 179 positions worth $2.78B, up 0.66% from $2.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management deployed $443M of net new capital in Q3 2015, opening 61 new positions and adding to 32 existing holdings. Its largest new stake was UnitedHealth: 312,600 shares worth $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 84% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was Amgen, an estimated $27.7M trimmed.

  • Tekla Capital Management's largest Q3 2015 buy was UnitedHealth: 312,600 shares worth $36.3M.
  • Tekla Capital Management added most to Biogen in Q3 2015, an estimated $37.6M increase.
  • Tekla Capital Management's biggest Q3 2015 reduction was Amgen, cutting an estimated $27.7M.
  • Tekla Capital Management fully exited CATAMARAN CORP COM STK (CDA) in Q3 2015, selling an estimated $26.5M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.78B portfolio in Q3 2015.
  • Tekla Capital Management opened 61 new positions and closed 19 in Q3 2015.
  • Tekla Capital Management's portfolio value rose 0.66% quarter-over-quarter to $2.78B.

Based on Tekla Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.